Arrivent Biopharma, INC. (AVBP) SEC Filings — 2025

Filings

• ArriVent's R&D Surge Drives 118% Net Loss Increase to $130.8M — 10-Q · Nov 10, 2025
• ArriVent BioPharma Files 8-K — 8-K · Sep 9, 2025
• ArriVent's Losses Widen Amid R&D Surge, Bolstered by $172.5M Offering — 10-Q · Aug 11, 2025
• ArriVent BioPharma Files 8-K Report — 8-K · Jul 21, 2025
• ArriVent BioPharma Enters Material Definitive Agreement — 8-K · Jul 2, 2025
• ArriVent BioPharma Files 8-K — 8-K · Jun 23, 2025
• ArriVent BioPharma Files 8-K on Shareholder Vote Matters — 8-K · Jun 20, 2025
• ArriVent BioPharma Files Q1 2025 10-Q — 10-Q · May 12, 2025
• ArriVent BioPharma Elects New Directors, Discloses Officer Compensation — 8-K · Apr 28, 2025
• ArriVent BioPharma Changes Auditors — 8-K · Mar 13, 2025
• ArriVent BioPharma Files 2024 10-K — 10-K · Mar 3, 2025
• ArriVent BioPharma Enters Material Definitive Agreement — 8-K · Jan 22, 2025